Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Ascending Doses of Fezagepras in Healthy Subjects
NCT04695041Phase 1Completed
- Sponsor
- Liminal BioSciences Inc.
- Start
- Dec 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fezagepras in fibrosis (6 arms), sponsored by Liminal BioSciences Inc. Primary endpoint: Safety and Tolerability. Started Dec 2020; status: completed.
02
Drugs
fezagepras
03
Conditions
fibrosis
Beyond the preview
Go deeper on NCT04695041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695041.